BWX Technologies, Inc. filings document the regulatory record of a NYSE-listed nuclear manufacturing and engineering company serving government and commercial markets. Its disclosures cover operating and financial results, segment performance, backlog-related business activity, risk factors, and material events connected to nuclear propulsion, nuclear fuel, and commercial nuclear operations.
BWXT’s SEC filings also address governance and capital structure. Recent records include proxy materials and annual meeting voting results, board and executive officer matters, registered common stock information, material agreements, and convertible senior notes due 2030 with related subsidiary guarantees.
BWX Technologies, Inc. (symbol: BWXT) is the issuer of record for a Form 4 filing submitted to the SEC. Richardson John M reported acquisition or exercise transactions in this Form 4 filing.
BWX Technologies, Inc. (BWXT) reported that director John M. Richardson received an automatic accrual of 16.44 Dividend Equivalent Rights (DERs) on September 4, 2026, in respect of previously granted restricted stock units for which he has elected to defer receipt of the underlying shares.
Each DER and each related restricted stock unit represents a contingent right to receive one share of BWXT common stock, and the DERs will be delivered to Richardson proportionately with the associated RSUs pursuant to his deferral election, bringing his directly held DER balance to 354.31.
BWX Technologies, Inc. (symbol: BWXT) is the issuer of record for a Form 4 filing submitted to the SEC. Bertsch Jan reported acquisition or exercise transactions in this Form 4 filing.
BWX Technologies, Inc. (BWXT) reported that director Jan Bertsch received a grant of 41.93 Dividend Equivalent Rights (DERs)2,284.41 DERs
BWX Technologies, Inc. (BWXT) reported that officer Suzanne Maddux, SVP, Operations, received equity awards on September 1, 2026. She was granted 5,727 Restricted Stock Units, vesting in three equal annual installments beginning September 1, 2027, and 1,257 employee stock options to buy common stock at an exercise price of $161.54 per share, also vesting in three equal annual installments beginning September 1, 2027. The stock options expire on September 1, 2036. All reported holdings are shown as directly owned.
BWX Technologies, Inc. (BWXT) filed an initial statement of beneficial ownership for Suzanne Maddux, who is identified as Senior Vice President, Operations. The filing reports no equity transactions and does not list any securities holdings or derivative positions for her at this time.
BWX Technologies, Inc. (BWXT) reported that Joseph Kirwan Miller, its President, Government Operations, settled 3,379 Restricted Stock Units into an equal number of shares of common stock on September 1, 2026, upon vesting. On the same date, 1,523 shares of common stock were delivered or withheld for payment of exercise price or tax liability at $152.29 per share. No Rule 10b5-1 trading plan is reported for these transactions.
BWX Technologies, Inc. President and CEO Rex D. Geveden reported open-market sales of a total of 10,000 shares of common stock on 2026-08-12, in multiple tranches at weighted average prices between $170.65 and $174.24 per share. All transactions were effected pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on 8/11/2025.
Rex D. Geveden, affiliated with BWX Technologies, Inc., plans to sell up to 10,000 shares of common stock through Charles Schwab & Co., Inc. on or after 08/12/2026 on the NYSE, with an indicated aggregate market value of $1,725,006.00. The shares derive from RSU/PSU equity compensation granted and acquired on 02/27/2023. In the prior three months, 10,000 BWX Technologies shares were sold for $2,048,124.00.
BWX Technologies, Inc. filed an amendment to its Q2 2026 quarterly report solely to add omitted iXBRL data; financial results remain unchanged. For the quarter ended June 30, 2026, revenue was $901,625 (in thousands), up 18.0% year over year, and net income attributable to the company was $89,014 (in thousands), or $0.97 per diluted share.
For the first six months, revenue reached $1,761,842 (in thousands) and net income was $180,084 (in thousands), driven by strong growth in Commercial Operations, where revenue rose to $586,158 (in thousands) and operating income to $48,361 (in thousands). Government Operations revenue increased to $1,179,191 (in thousands) while operating income edged slightly lower to $204,819 (in thousands) after prior-year contract catch-up benefits.
Operating cash flow was $249,003 (in thousands) for the first half, and cash and restricted cash totaled $616,273 (in thousands) with no borrowings under a $1.25 billion revolving credit facility. Backlog stood at $8,398.1 million, about 55% expected to be recognized as revenue by the end of 2027. Recent moves include the acquisitions of Aerojet Ordnance Tennessee and Kinectrics, the July 2026 purchase of Precision Components Group, and an agreement to sell the medical business to Nordic Capital for up to $800 million while retaining a minority interest.
BWX Technologies, Inc. reported higher results for the quarter and six months ended June 30, 2026. Second‑quarter revenue was $901.6 million, up from $764.0 million, and net income attributable to BWXT was $89.0 million, compared with $78.4 million. Diluted EPS was $0.97 versus $0.85.
For the first half of 2026, revenue rose to $1.76 billion and net income attributable to BWXT to $180.1 million. Commercial Operations grew sharply, with revenue of $586.2 million and operating income of $48.4 million, helped by the 2025 Kinectrics acquisition, while Government Operations revenue increased modestly and operating income was slightly lower.
Cash from operating activities increased to $249.0 million in the first half, and cash and restricted cash totaled $616.3 million at June 30, 2026 against $2.02 billion of long‑term debt. Backlog reached $8.40 billion, with about 55% expected to be recognized as revenue by the end of 2027. BWXT completed the acquisition of Precision Components Group on July 1, 2026 and agreed to sell its medical business to Nordic Capital in a transaction valued at up to $800 million, retaining a minority interest and providing ongoing isotope and radiochemical support.
BWX Technologies reported strong second quarter 2026 results, with revenue of $901.6 million, up 18% year over year, and GAAP net income of $89.1 million, up 14%. GAAP diluted EPS rose to $0.97, non-GAAP EPS to $1.07, and consolidated adjusted EBITDA reached $155.5 million, a 7% increase. Commercial Operations revenue grew 72% to $302.5 million, while Government Operations revenue increased 2% to $601.3 million. Free cash flow was $115.0 million versus $126.3 million a year earlier, reflecting higher capital expenditures.
The company announced the sale of its medical business to sharpen focus on nuclear national defense and commercial nuclear power, and closed the acquisition of Precision Components Group on July 1, 2026, adding a U.S. commercial nuclear manufacturing footprint. Total backlog increased to 8,398,081 (in thousands) from 6,015,191 (in thousands) a year earlier. Reflecting a strong first half and the PCG contribution, BWXT raised 2026 guidance to revenue of approximately $3,800 million, adjusted EBITDA of $662–$672 million, non-GAAP EPS of $4.70–$4.80, and free cash flow of $345–$360 million. The board declared a quarterly dividend of $0.27 per share payable September 4, 2026.